摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[4-[(4-methoxycarbonyl)oxazol-2-yl]thiazol-2-yl]-6-[4-[(4-methoxycarbonyl)oxazol-2-yl]oxazol-2-yl]pyridine | 1221966-09-1

中文名称
——
中文别名
——
英文名称
2-[4-[(4-methoxycarbonyl)oxazol-2-yl]thiazol-2-yl]-6-[4-[(4-methoxycarbonyl)oxazol-2-yl]oxazol-2-yl]pyridine
英文别名
Methyl 2-[2-[6-[4-(4-methoxycarbonyl-1,3-oxazol-2-yl)-1,3-thiazol-2-yl]pyridin-2-yl]-1,3-oxazol-4-yl]-1,3-oxazole-4-carboxylate
2-[4-[(4-methoxycarbonyl)oxazol-2-yl]thiazol-2-yl]-6-[4-[(4-methoxycarbonyl)oxazol-2-yl]oxazol-2-yl]pyridine化学式
CAS
1221966-09-1
化学式
C21H13N5O7S
mdl
——
分子量
479.43
InChiKey
HSSXUCLGVIAAGB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    34
  • 可旋转键数:
    8
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    185
  • 氢给体数:
    0
  • 氢受体数:
    13

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-[4-[(4-methoxycarbonyl)oxazol-2-yl]thiazol-2-yl]-6-[4-[(4-methoxycarbonyl)oxazol-2-yl]oxazol-2-yl]pyridine 、 lithium hydroxide 作用下, 以 四氢呋喃 为溶剂, 以78%的产率得到2-[2-[6-[4-(4-Carboxy-1,3-oxazol-2-yl)-1,3-thiazol-2-yl]pyridin-2-yl]-1,3-oxazol-4-yl]-1,3-oxazole-4-carboxylic acid
    参考文献:
    名称:
    Macrocyclic Pyridyl Polyoxazoles: Selective RNA and DNA G-Quadruplex Ligands as Antitumor Agents
    摘要:
    The synthesis of a series of 24-membered pyridine-containing polyoxazole macrocycles is described. Seventeen new macrocycles were evaluated for cytotoxic activity against RPMI 8402, KB-3, and KB-3 cell lines that overexpress the efflux transporters MDR1 (KBV-1) and BCRP (KBH5.0). Macrocycles in which the pyridyl-polyoxazole moiety is linked by a 1,3-bis(aminomethyl)phenyl group with a 5-(2-aminoethyl)- (18) or a 5-(2-dimethylaminoethyl)- substituent (19) displayed the greatest cytotoxic potency. These compounds exhibit exquisite selectivity for stabilizing G-quadruplex DNA with no stabilization of duplex DNA or RNA. Compound 19 stabilizes quadruplex mRNA that encodes the cell-cycle checkpoint protein kinase Aurora A to a greater extent than the quadruplex DNA of a human telomeric sequence. These data may suggest a role for G-quadruplex ligands interacting with mRNA being associated with the biological activity of macrocyclic polyoxazoles. Compound 19 has significant in vivo anticancer activity against a human breast cancer xenograft (MDA-MB-435) in athymic nude mice.
    DOI:
    10.1021/jm1000612
  • 作为产物:
    描述:
    Methyl 2-[2-[6-[4-(4-methoxycarbonyl-1,3-oxazol-2-yl)-4,5-dihydro-1,3-thiazol-2-yl]pyridin-2-yl]-4,5-dihydro-1,3-oxazol-4-yl]-1,3-oxazole-4-carboxylate三氯溴甲烷1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下, 以 乙腈 为溶剂, 以57 mg的产率得到2-[4-[(4-methoxycarbonyl)oxazol-2-yl]thiazol-2-yl]-6-[4-[(4-methoxycarbonyl)oxazol-2-yl]oxazol-2-yl]pyridine
    参考文献:
    名称:
    Macrocyclic Pyridyl Polyoxazoles: Selective RNA and DNA G-Quadruplex Ligands as Antitumor Agents
    摘要:
    The synthesis of a series of 24-membered pyridine-containing polyoxazole macrocycles is described. Seventeen new macrocycles were evaluated for cytotoxic activity against RPMI 8402, KB-3, and KB-3 cell lines that overexpress the efflux transporters MDR1 (KBV-1) and BCRP (KBH5.0). Macrocycles in which the pyridyl-polyoxazole moiety is linked by a 1,3-bis(aminomethyl)phenyl group with a 5-(2-aminoethyl)- (18) or a 5-(2-dimethylaminoethyl)- substituent (19) displayed the greatest cytotoxic potency. These compounds exhibit exquisite selectivity for stabilizing G-quadruplex DNA with no stabilization of duplex DNA or RNA. Compound 19 stabilizes quadruplex mRNA that encodes the cell-cycle checkpoint protein kinase Aurora A to a greater extent than the quadruplex DNA of a human telomeric sequence. These data may suggest a role for G-quadruplex ligands interacting with mRNA being associated with the biological activity of macrocyclic polyoxazoles. Compound 19 has significant in vivo anticancer activity against a human breast cancer xenograft (MDA-MB-435) in athymic nude mice.
    DOI:
    10.1021/jm1000612
点击查看最新优质反应信息

文献信息

  • THERAPEUTIC COMPOUNDS
    申请人:LaVoie Edmond J.
    公开号:US20120238595A1
    公开(公告)日:2012-09-20
    The invention provides compounds of formula (I) wherein u, d, v, m, n, R 1 , W, X, Y, and Z have any values defined herein, as well as salts thereof. The compounds have activity as anti-proliferative agents.
  • US8796300B2
    申请人:——
    公开号:US8796300B2
    公开(公告)日:2014-08-05
  • [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSÉS THÉRAPEUTIQUES
    申请人:UNIV RUTGERS
    公开号:WO2011057126A1
    公开(公告)日:2011-05-12
    The invention provides compounds of formula (I) wherein u, d, v, m, n, R1, W, X, Y, and Z have any values defined herein, as well as salts thereof. The compounds have activity as anti-proliferative agents.
查看更多